TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02877342

Intervention type: OTHER
Intervention: Pre-hospital notification
Description: Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
Study: NCT00964977

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
Study: NCT02175680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: CCR5 Antagonist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Historical data
Description: Historical data (i.e., time to HIV-1 RNA viral load \> 500 copies/mL of 29 days).
Study: NCT03357627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets.
Study: NCT03612986

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SYALOX® 300 Plus
Description: Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator. No chemical effect expected
Study: NCT02692066

Intervention type: BIOLOGICAL
Intervention: varicella vaccine

Intervention type: BIOLOGICAL
Intervention: varicella vaccine
Study: NCT01060059

Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Intervention: basal insulin
Description: subcutaneous injection, dosing according to physician's clinical judgment
Study: NCT04397094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theracal LC
Description: pulpotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Pulpotomy
Study: NCT00501813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatectomy
Description: irregular Hepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE combined with local regional therapies without hepatectomy
Description: TACE combined with RFA, MCT, PEI, and so on.
Study: NCT03575858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barrel shaped interdental brush
Description: Barrel shaped interdental brush Size SS 0.8mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered interdental brush
Description: Tapered interdental brush Size SS 0.6mm
Study: NCT01459458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning-based Partner Violence Intervention
Description: The intervention includes three major components:~1. Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~2. Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~3. Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed.
Study: NCT01035905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Daily disposable contact lens worn in a daily wear, daily disposable mode
Study: NCT02448732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACM-1
Description: intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
Study: NCT00091832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab administered by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Bisphosphonates
Description: Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
Study: NCT04369066

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples (collection of 5 mL of blood in a dry tube)
Description: A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swabs
Description: The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total.
Study: NCT02972164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss program for school children
Description: The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being.
Study: NCT00740350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Logan Basic
Description: Logan Basic chiropractic adjustments during pregnancy.
Study: NCT04490837

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA and Rapid test to detect antibodies against COVID-19
Description: Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA and Rapid test to detect antibodies against COVID-19
Description: Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA and Rapid test to detect antibodies against COVID-19
Description: Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices
Study: NCT02067039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick in home & Sure Check HIV tests
Description: Provision of OraQuick in home \& Sure Check HIV tests
Study: NCT04385654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
Study: NCT01972074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT02508194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7510
Description: RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IIV
Description: Marketed Inactivated Influenza Vaccine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sterile Saline
Study: NCT02235194

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino Acid and chromium-picolinate containing drink
Description: Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid and chromium-picolinate containing drink
Description: Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink ist taken with a test meal to study efects on glucose and insulin response.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drink
Description: Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
Study: NCT00393874

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Sleep Intervention
Description: Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
Study: NCT02113631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
Study: NCT03434379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle
Study: NCT01407549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness group meetings with psychologist
Description: The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
Study: NCT03064841

Intervention type: DRUG
Intervention: No Treatment
Description: No treatment
Study: NCT03434977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granule formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granule formulation
Study: NCT03899662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Cognitive training included memory, attention, velocity, intelligence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Physical training included aerobic, strength, flexibility and balance.
Study: NCT01347736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scrambler therapy
Description: Undergo scrambler therapy
Study: NCT02145819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LH peak
Study: NCT01347736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dermatologic complications management/prevention
Description: Undergo scrambler therapy
Study: NCT04654208

Intervention type: DRUG
Intervention: palbociclib
Description: patients on palbociclib combination treatment

Intervention type: DRUG
Intervention: palbociclib
Description: patients on palbociclib combination treatment
Study: NCT03068156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Description: monochromator UVB laser (308nm)
Study: NCT02333617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip and core strengthening exercises
Description: Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hip and core strengthening exercises
Description: Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip and core strengthening exercises
Description: Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
Study: NCT00576329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: Topical use before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Topical use before surgery
Study: NCT02055066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-111
Study: NCT02456779

Intervention type: OTHER
Intervention: Questionnaire
Description: all recruited subjects to complete the RDQ as a determinant of inclusion criteria

Intervention type: OTHER
Intervention: Questionnaire
Description: control subjects to complete RSI as a determinant of inclusion criteria
Study: NCT02129946

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistant Starch
Description: In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
Study: NCT00040755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebimastat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02031705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cavotricuspid isthmus ablation
Description: Isthmus ablation was performed in paroxysmal atrial fibrillation patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Control group was performed no additional cavotricuspid isthmus ablation.
Study: NCT01699555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GNbAC1 placebo
Description: Single dose intravenous (IV) GNbAC1 placebo
Study: NCT02271412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00538720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Four-dimensional computed tomography (4DCT)
Description: Four-dimensional computed tomography (4DCT) scan of the neck.
Study: NCT02734251

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relora
Description: 750 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02715440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Description: Gradual withdrawal of benzodiazepines or related drugs
Study: NCT02886403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: A standard adhesive strip (hydrocolloid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: A newly developed adhesive strip